Affordable Access

deepdyve-link
Publisher Website

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.

Authors
  • Deering, Raquel P
  • Kommareddy, Sushma
  • Ulmer, Jeffrey B
  • Brito, Luis A
  • Geall, Andrew J
Type
Published Article
Journal
Expert Opinion on Drug Delivery
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jun 01, 2014
Volume
11
Issue
6
Pages
885–899
Identifiers
DOI: 10.1517/17425247.2014.901308
PMID: 24665982
Source
Medline
Keywords
License
Unknown

Abstract

The prospects for mRNA vaccines are very promising. Like other types of nucleic acid vaccines, mRNA vaccines have the potential to combine the positive attributes of live attenuated vaccines while obviating many potential safety limitations. Although data from initial clinical trials appear encouraging, mRNA vaccines are far from a commercial product. These initial approaches have spurred innovations in vector design, non-viral delivery, large-scale production and purification of mRNA to quickly move the technology forward. Some improvements have already been tested in preclinical models for both prophylactic and therapeutic vaccine targets and have demonstrated their ability to elicit potent and broad immune responses, including functional antibodies, type 1 T helper cells-type T cell responses and cytotoxic T cells. Though the initial barriers for this nucleic acid vaccine approach seem to be overcome, in our opinion, the future and continued success of this approach lies in a more extensive evaluation of the many non-viral delivery systems described in the literature and gaining a better understanding of the mechanism of action to allow rational design of next generation technologies.

Report this publication

Statistics

Seen <100 times